![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: CCL19 |
Gene summary for CCL19 |
![]() |
Gene information | Species | Human | Gene symbol | CCL19 | Gene ID | 6363 |
Gene name | C-C motif chemokine ligand 19 | |
Gene Alias | CKb11 | |
Cytomap | 9p13.3 | |
Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | Q6IBD6 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
6363 | CCL19 | P1_S1_AK | Human | Skin | AK | 3.65e-06 | -4.94e-01 | -0.3399 |
6363 | CCL19 | P2_S3_AK | Human | Skin | AK | 1.71e-10 | -5.33e-01 | -0.3287 |
6363 | CCL19 | P2_S4_SCCIS | Human | Skin | SCCIS | 2.56e-11 | -5.25e-01 | -0.3043 |
6363 | CCL19 | P3_S6_AK | Human | Skin | AK | 1.68e-10 | -5.20e-01 | -0.3256 |
6363 | CCL19 | P5_S10_cSCC | Human | Skin | cSCC | 2.44e-13 | -5.45e-01 | -0.299 |
6363 | CCL19 | P1_cSCC | Human | Skin | cSCC | 2.41e-05 | -5.30e-01 | 0.0292 |
6363 | CCL19 | P2_cSCC | Human | Skin | cSCC | 2.02e-08 | -5.05e-01 | -0.024 |
6363 | CCL19 | P4_cSCC | Human | Skin | cSCC | 4.03e-04 | -4.09e-01 | -0.00290000000000005 |
6363 | CCL19 | P10_cSCC | Human | Skin | cSCC | 6.51e-09 | -5.30e-01 | 0.1017 |
6363 | CCL19 | cSCC_p1 | Human | Skin | cSCC | 2.94e-15 | -5.42e-01 | -0.1916 |
6363 | CCL19 | cSCC_p10 | Human | Skin | cSCC | 8.39e-12 | -5.41e-01 | -0.2095 |
6363 | CCL19 | cSCC_p11 | Human | Skin | cSCC | 4.98e-17 | -5.32e-01 | -0.2102 |
6363 | CCL19 | cSCC_p3 | Human | Skin | cSCC | 7.47e-05 | -4.61e-01 | -0.2085 |
6363 | CCL19 | cSCC_p4 | Human | Skin | cSCC | 2.63e-09 | -5.23e-01 | -0.2022 |
6363 | CCL19 | cSCC_p6 | Human | Skin | cSCC | 7.40e-09 | -4.91e-01 | -0.1989 |
6363 | CCL19 | cSCC_p7 | Human | Skin | cSCC | 6.61e-15 | -5.43e-01 | -0.2332 |
6363 | CCL19 | cSCC_p8 | Human | Skin | cSCC | 5.31e-12 | -5.15e-01 | -0.1971 |
6363 | CCL19 | cSCC_p9 | Human | Skin | cSCC | 2.92e-13 | -5.28e-01 | -0.1991 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Skin | ![]() | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma | ||
SCCIS:squamous cell carcinoma in situ |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:007190024 | Skin | cSCC | regulation of protein serine/threonine kinase activity | 123/4864 | 359/18723 | 2.70e-04 | 2.17e-03 | 123 |
GO:003287225 | Skin | cSCC | regulation of stress-activated MAPK cascade | 72/4864 | 192/18723 | 2.76e-04 | 2.22e-03 | 72 |
GO:003134622 | Skin | cSCC | positive regulation of cell projection organization | 120/4864 | 353/18723 | 4.49e-04 | 3.44e-03 | 120 |
GO:000257324 | Skin | cSCC | myeloid leukocyte differentiation | 76/4864 | 208/18723 | 4.75e-04 | 3.60e-03 | 76 |
GO:007134613 | Skin | cSCC | cellular response to interferon-gamma | 47/4864 | 118/18723 | 6.71e-04 | 4.79e-03 | 47 |
GO:003461226 | Skin | cSCC | response to tumor necrosis factor | 88/4864 | 253/18723 | 1.11e-03 | 7.31e-03 | 88 |
GO:19012248 | Skin | cSCC | positive regulation of NIK/NF-kappaB signaling | 30/4864 | 69/18723 | 1.19e-03 | 7.75e-03 | 30 |
GO:001988227 | Skin | cSCC | antigen processing and presentation | 42/4864 | 106/18723 | 1.42e-03 | 8.98e-03 | 42 |
GO:190370626 | Skin | cSCC | regulation of hemopoiesis | 120/4864 | 367/18723 | 2.23e-03 | 1.32e-02 | 120 |
GO:007135625 | Skin | cSCC | cellular response to tumor necrosis factor | 79/4864 | 229/18723 | 2.48e-03 | 1.42e-02 | 79 |
GO:009858622 | Skin | cSCC | cellular response to virus | 34/4864 | 84/18723 | 2.56e-03 | 1.45e-02 | 34 |
GO:000725423 | Skin | cSCC | JNK cascade | 60/4864 | 167/18723 | 2.77e-03 | 1.56e-02 | 60 |
GO:003367425 | Skin | cSCC | positive regulation of kinase activity | 148/4864 | 467/18723 | 3.00e-03 | 1.66e-02 | 148 |
GO:004578529 | Skin | cSCC | positive regulation of cell adhesion | 139/4864 | 437/18723 | 3.39e-03 | 1.84e-02 | 139 |
GO:004632823 | Skin | cSCC | regulation of JNK cascade | 49/4864 | 133/18723 | 3.64e-03 | 1.95e-02 | 49 |
GO:00380616 | Skin | cSCC | NIK/NF-kappaB signaling | 52/4864 | 143/18723 | 3.83e-03 | 2.05e-02 | 52 |
GO:19012225 | Skin | cSCC | regulation of NIK/NF-kappaB signaling | 42/4864 | 112/18723 | 4.71e-03 | 2.40e-02 | 42 |
GO:003010024 | Skin | cSCC | regulation of endocytosis | 72/4864 | 211/18723 | 5.06e-03 | 2.56e-02 | 72 |
GO:005123527 | Skin | cSCC | maintenance of location | 106/4864 | 327/18723 | 5.17e-03 | 2.61e-02 | 106 |
GO:190210524 | Skin | cSCC | regulation of leukocyte differentiation | 92/4864 | 279/18723 | 5.20e-03 | 2.63e-02 | 92 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
CCL19 | CCR7 | CCL19_CCR7 | CCL | GC | ADJ |
CCL19 | CCR7 | CCL19_CCR7 | CCL | GC | GC |
CCL19 | CCR7 | CCL19_CCR7 | CCL | HNSCC | Precancer |
CCL19 | ACKR4 | CCL19_ACKR4 | CCL | HNSCC | Precancer |
CCL19 | CCR7 | CCL19_CCR7 | CCL | Lung | IAC |
CCL19 | CCR7 | CCL19_CCR7 | CCL | Prostate | Tumor |
CCL19 | CCR7 | CCL19_CCR7 | CCL | Skin | ADJ |
CCL19 | ACKR4 | CCL19_ACKR4 | CCL | Skin | ADJ |
CCL19 | CCR7 | CCL19_CCR7 | CCL | Skin | AK |
CCL19 | ACKR4 | CCL19_ACKR4 | CCL | Skin | AK |
CCL19 | CCR7 | CCL19_CCR7 | CCL | Skin | cSCC |
CCL19 | ACKR4 | CCL19_ACKR4 | CCL | Skin | cSCC |
CCL19 | CCR7 | CCL19_CCR7 | CCL | Skin | Healthy |
CCL19 | CCR7 | CCL19_CCR7 | CCL | Skin | SCCIS |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CCL19 | SNV | Missense_Mutation | novel | c.241N>T | p.Arg81Cys | p.R81C | Q99731 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CCL19 | SNV | Missense_Mutation | rs199848815 | c.242N>A | p.Arg81His | p.R81H | Q99731 | protein_coding | deleterious(0.05) | probably_damaging(0.998) | TCGA-AJ-A3EK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
CCL19 | SNV | Missense_Mutation | novel | c.91N>A | p.Leu31Met | p.L31M | Q99731 | protein_coding | deleterious(0.02) | probably_damaging(0.999) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
CCL19 | SNV | Missense_Mutation | novel | c.49N>T | p.Ala17Ser | p.A17S | Q99731 | protein_coding | tolerated(0.2) | benign(0) | TCGA-DF-A2KN-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
CCL19 | SNV | Missense_Mutation | rs775824329 | c.10C>A | p.Leu4Ile | p.L4I | Q99731 | protein_coding | tolerated_low_confidence(0.06) | benign(0.089) | TCGA-44-8120-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
CCL19 | SNV | Missense_Mutation | rs556438266 | c.218N>G | p.Pro73Arg | p.P73R | Q99731 | protein_coding | deleterious(0) | probably_damaging(0.971) | TCGA-43-2576-01 | Lung | lung squamous cell carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
CCL19 | SNV | Missense_Mutation | rs199848815 | c.242N>A | p.Arg81His | p.R81H | Q99731 | protein_coding | deleterious(0.05) | probably_damaging(0.998) | TCGA-BR-8680-01 | Stomach | stomach adenocarcinoma | Male | <65 | III/IV | Chemotherapy | oxaliplatin | CR |
CCL19 | SNV | Missense_Mutation | c.127N>A | p.Val43Met | p.V43M | Q99731 | protein_coding | deleterious(0) | probably_damaging(0.91) | TCGA-CD-8536-01 | Stomach | stomach adenocarcinoma | Male | >=65 | I/II | Chemotherapy | epirubicin | CR |
Page: 1 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |